SAB Biotherapeutics, Inc. (SABSW) shareholders
SABSWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SABS
$0.01+0.00 (+33.33%)
Close on Oct 20, 2026Market cap $304.80MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
1M
Shares held, 13F filers
Institutional holders
8
2 new, 0 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. Joint filing with Vivo Opportunity, LLC (9.99%), Vivo Opportunity Cayman Fund, L.P. (9.99%) and 1 more | 22,637,108 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| RA Capital Healthcare Fund, L.P. Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 9,609,852 | 9.90% | 13D (active) amendment | Aug 6, 2026 |
| Michael Kramarz Joint filing with Commodore Capital LP (9.90%), Commodore Capital Master LP (9.90%) and 1 more | 8,948,170 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| Johnson David Edward Joint filing with Caligan Partners LP (10.40%) | 7,967,207 | 10.40% | 13G (passive) | Mar 31, 2026 |
| Caligan Partners LP Joint filing with Johnson David Edward (8.80%) | 7,967,207 | 8.80% | 13G (passive) amendment | Jun 30, 2026 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more | 7,311,225 | 9.90% | 13D (active) amendment | Mar 19, 2026 |
| Dames GP LLC Joint filing with Balyasny Asset Management L.P. (9.45%), Bam Gp LLC (9.45%) and 2 more | 7,225,439 | 9.45% | 13G (passive) amendment | Jun 30, 2026 |
| Perceptive Advisors LLC Joint filing with Joseph Edelman (7.30%), Perceptive Life Sciences Master Fund, Ltd. (7.30%) | 6,627,501 | 7.30% | 13G (passive) amendment | Jun 30, 2026 |
| Perceptive Life Sciences Master Fund, Ltd. Joint filing with Perceptive Advisors LLC (8.40%), Joseph Edelman (8.40%) | 6,431,743 | 8.40% | 13G (passive) amendment | Mar 31, 2026 |
| Phillip Gross Joint filing with Adage Capital Management, L.P. (8.38%), Robert Atchinson (8.38%) | 6,405,553 | 8.38% | 13G (passive) | Jun 30, 2026 |
| Woodline Partners LP | 5,455,355 | 6.80% | 13G (passive) amendment | Jun 30, 2026 |
| RA Capital Management, L.P. Joint filing with Peter Kolchinsky (9.90%), Rajeev Shah (9.90%) and 1 more | 5,166,424 | 9.90% | 13D (active) amendment | Mar 9, 2026 |
| Bam Gp LLC Joint filing with Balyasny Asset Management L.P. (9.99%), Balyasny Asset Management Holdings LP (9.99%) and 2 more | 5,089,939 | 9.99% | 13G (passive) | Mar 31, 2026 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (9.10%), Bvf Inc/Il (9.10%) and 3 more | 4,761,906 | 9.10% | 13G (passive) amendment | Dec 31, 2025 |
| Commodore Capital LP Joint filing with Commodore Capital Master LP (9.90%), Robert Egen Atkinson (9.90%) and 1 more | 4,522,977 | 9.90% | 13G (passive) | Sep 26, 2025 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (7.30%), Perceptive Life Sciences Master Fund, Ltd. (7.30%) | 3,471,861 | 7.30% | 13G (passive) | Jan 14, 2026 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.10%), Israel A. Englander (5.10%) | 3,432,153 | 5.10% | 13G (passive) | Apr 24, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SABSW | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| LMR Partners LLP | 539,588 | – | $6.91K | – | 0.00% |
| Morgan Stanley | 146,439 | – | $1.87K | – | 0.00% |
| Clear Street Group Inc. | 79,033 | – | $1.01K | +300 | 0.00% |
| Gts Securities LLC | 41,301 | – | $537 | +300 | 0.00% |
| Virtu Financial LLC | 21,223 | – | $0 | New | 0.00% |
| UBS Group AG | 6,567 | – | $85 | +2,381 | 0.00% |
| Wolverine Asset Management LLC | 3,289 | – | $42 | +1,478 | 0.00% |
| Toronto Dominion Bank | 300 | – | $4 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 8 | 1M | 2 / 4 | 0 / 0 | 0M | 0M |
| Q1 2026 | 6 | 1M | 1 / 0 | 3 / 2 | 1M | 0M |
| Q4 2025 | 7 | 0M | 1 / 0 | 3 / 4 | 0M | 1M |
| Q3 2025 | 10 | 1M | 5 / 0 | 2 / 0 | 0M | 0M |
| Q2 2025 | 6 | 1M | 1 / 0 | 0 / 2 | 0M | 0M |
| Q1 2025 | 7 | 1M | 0 / 1 | 3 / 2 | 0M | 0M |
| Q4 2024 | 9 | 1M | 2 / 1 | 3 / 2 | 1M | 0M |
| Q3 2024 | 9 | 1M | 2 / 1 | 0 / 4 | 0M | 1M |
| Q2 2024 | 11 | 1M | 1 / 1 | 3 / 2 | 0M | 0M |
| Q1 2024 | 12 | 1M | 3 / 1 | 2 / 1 | 0M | 0M |
| Q4 2023 | 10 | 1M | 1 / 9 | 0 / 0 | 1M | 0M |
| Q3 2023 | 9 | 0M | 1 / 1 | 0 / 2 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Samuel J. Reich | CEO, Director | 766,699 | Feb 5, 2026 |
| Eddie Joe Sullivan | PRESIDENT, Director | 5,232,304 | Feb 5, 2026 |
| Alexandra Kropotova | CHIEF MEDICAL OFFICER | 41,853 | Sep 18, 2026 |
| Lucy To | See Remarks | – | Feb 5, 2026 |
| Christoph Lawrence Bausch | CHIEF OPERATING OFFICER | – | Feb 5, 2026 |
| Rita Jain | Director | – | Jan 7, 2026 |
| David Zaccardelli | Director | – | Jan 7, 2026 |
| David Link | Director | – | Dec 18, 2025 |
| Erick Lucera | Director | – | Dec 18, 2025 |
| Jay S. Skyler | Director | – | Dec 18, 2025 |
| William James Polvino | Director | – | Dec 18, 2025 |
| Scott Giberson | Director | – | Dec 18, 2025 |
| Helen K. Ellias | Director | 2,857,142 | Dec 18, 2025 |
| John Petry | Director | – | Oct 1, 2025 |
| Sessa Capital GP, LLC | Director | 2,198,457 | Oct 1, 2025 |
| Andrew Moin | Director | 2,198,457 | Oct 1, 2025 |
| Sessa Capital IM, L.P. | Director | – | Oct 1, 2025 |
| Sessa Capital IM GP, LLC | Director | 4,584,571 | Oct 1, 2025 |
| Sessa Capital (Master), L.P. | Director | – | Oct 1, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Alexandra Kropotova CHIEF MEDICAL OFFICER | Sep 17, 2026 | Tax withholding | −473 | – | – | 41,853 |
| Alexandra Kropotova CHIEF MEDICAL OFFICER | Jun 25, 2026 | Tax withholding | −988 | – | – | 42,308 |
| Alexandra Kropotova CHIEF MEDICAL OFFICER | Mar 24, 2026 | Tax withholding | −988 | – | – | 43,296 |
| Alexandra Kropotova CHIEF MEDICAL OFFICER | Dec 11, 2025 | Tax withholding | −988 | – | – | 44,284 |
| Sessa Capital GP, LLC Director | Sep 29, 2025 | Option exercise | +1,740,000 | $1.75 | $3.05M | 2,198,457 |
| Andrew Moin Director | Sep 29, 2025 | Option exercise | +1,740,000 | $1.75 | $3.05M | 2,198,457 |
| Alexandra Kropotova CHIEF MEDICAL OFFICER | Sep 19, 2025 | Tax withholding | −1,977 | – | – | 45,272 |
| Alexandra Kropotova CHIEF MEDICAL OFFICER | Mar 27, 2025 | Tax withholding | −1,179 | – | – | 47,249 |
| Alexandra Kropotova CHIEF MEDICAL OFFICER | Dec 18, 2024 | Tax withholding | −9,072 | – | – | 48,428 |
| Eddie Joe Sullivan Chief Executive Officer, Director | Dec 7, 2023 | Buy | +1,740 | $0.88 | $1.53K | 5,232,304 |
| Michael King CHIEF FINANCIAL OFFICER | Nov 30, 2023 | Buy | +5,000 | $0.90 | $4.50K | 5,000 |
| Samuel J. Reich Executive Chairman, Director | Nov 29, 2023 | Buy | +11,000 | $0.89 | $9.79K | 219,001 |
| Sessa Capital IM GP, LLC Director | Nov 24, 2023 | Option exercise | +4,584,571 | – | – | 4,584,571 |
| Helen K. Ellias Director | Nov 24, 2023 | Option exercise | +2,857,142 | – | – | 2,857,142 |
| Andrew Moin Director | Nov 24, 2023 | Option exercise | +4,584,571 | – | – | 4,584,571 |
| Alexandra Kropotova Chief Medical Officer | Mar 14, 2023 | Award | +275,000 | – | – | 275,000 |
| David Charles Link Director | Dec 7, 2022 | Award | +41,493 | $1.21 | $50.21K | 57,313 |
| Jeffrey G. Spragens Director | Dec 7, 2022 | Award | +82,987 | $1.21 | $100.41K | 394,989 |
| Christine E. Hamilton Director, 10% owner | Dec 7, 2022 | Award | +82,987 | $1.21 | $100.41K | 3,111,334 |
| Christine E. Hamilton Director, 10% owner | Sep 13, 2022 | Buy | +10,000 | $0.73 | $7.30K | 4,993,090 |
| Eddie Joe Sullivan CHIEF EXECUTIVE OFFICER, Director, 10% owner | Sep 7, 2022 | Buy | +14,000 | $0.74 | $10.36K | 5,230,564 |
| Christine E. Hamilton Director, 10% owner | Jun 7, 2022 | Gift | −2,000,000 | – | – | 3,083,270 |
| Alexandra Kropotova Chief Medical Officer | Jun 6, 2022 | Award | +300,000 | – | – | 300,000 |
| Jeffrey G. Spragens Director | May 20, 2022 | Other | +299,002 | – | – | 312,002 |
| Samuel J. Reich Executive Chairman, Director | May 20, 2022 | Other | −2,500,127 | – | – | 547,698 |
| Samuel J. Reich Executive Chairman, Director | May 20, 2022 | Other | +207,001 | – | – | 208,001 |
| Russell P. Beyer Chief Financial Officer | Oct 26, 2021 | Sale | −278 | $7.90 | $2.20K | 0 |
| Russell P. Beyer Chief Financial Officer | Oct 25, 2021 | Award | +129 | $7.78 | $1.00K | 278 |
| Christine E. Hamilton Director, 10% owner | Oct 22, 2021 | Award | +4,974,497 | – | – | 4,974,497 |
| Christine E. Hamilton Director, 10% owner | Oct 22, 2021 | Award | +5,049,351 | – | – | 5,049,351 |
| Thomas Charles Luke Chief Medical Officer | Oct 22, 2021 | Award | +5,428 | – | – | 5,428 |
| Eddie Joe Sullivan Chief Executive Officer, Director, 10% owner | Oct 22, 2021 | Award | +5,213,764 | – | – | 5,213,764 |
| Edward D. Hamilton 10% owner | Oct 22, 2021 | Award | +4,974,497 | – | – | 4,974,497 |
| Edward D. Hamilton 10% owner | Oct 22, 2021 | Award | +5,049,351 | – | – | 5,049,351 |
| Frederick Finnegan Chief Business Officer | Oct 22, 2021 | Award | +38,596 | – | – | 38,596 |
| David Charles Link Director | Oct 22, 2021 | Award | +12,097 | – | – | 12,097 |
| David Charles Link Director | Oct 22, 2021 | Award | +15,820 | – | – | 15,820 |
| Thomas Charles Luke Chief Medical Officer | Oct 19, 2021 | Award | +990 | $10.10 | $10.00K | 990 |
| Russell P. Beyer Chief Financial Officer | Oct 18, 2021 | Award | +2,475 | $10.10 | $25.00K | 2,475 |
| Christine E. Hamilton Director, 10% owner | Oct 14, 2021 | Award | +5,092 | $10.10 | $51.43K | 5,092 |
| Edward D. Hamilton 10% owner | Oct 14, 2021 | Award | +5,092 | $10.10 | $51.43K | 5,092 |
| Samuel J. Reich CEO and CFO, Director, 10% owner | Oct 14, 2021 | Buy | +1,000 | $10.11 | $10.11K | 1,000 |
| Christine E. Hamilton Director, 10% owner | Oct 13, 2021 | Award | +20,800 | $10.10 | $210.08K | 20,800 |
| Edward D. Hamilton 10% owner | Oct 13, 2021 | Award | +20,800 | $10.10 | $210.08K | 20,800 |
| Ilan Katz Director, 10% owner | Oct 13, 2021 | Buy | +500 | $10.11 | $5.06K | 1,500 |
| Christine E. Hamilton Director, 10% owner | Oct 12, 2021 | Award | +25,000 | $10.09 | $252.25K | 25,000 |
| Christine E. Hamilton Director, 10% owner | Oct 12, 2021 | Award | +25,000 | $10.08 | $252.00K | 25,000 |
| Edward D. Hamilton 10% owner | Oct 12, 2021 | Award | +25,000 | $10.08 | $252.00K | 25,000 |
| Edward D. Hamilton 10% owner | Oct 12, 2021 | Award | +25,000 | $10.09 | $252.25K | 25,000 |
| Eddie Joe Sullivan Chief Executive Officer, Director, 10% owner | Oct 7, 2021 | Award | +2,800 | $10.07 | $28.20K | 2,800 |
| Christine E. Hamilton Director, 10% owner | Oct 1, 2021 | Award | +2,695 | $10.10 | $27.22K | 2,695 |
| Edward D. Hamilton 10% owner | Oct 1, 2021 | Award | +2,695 | $10.10 | $27.22K | 2,695 |
| Ilan Katz Director, 10% owner | Oct 1, 2021 | Buy | +1,000 | $10.09 | $10.09K | 1,000 |
| Jeffrey G. Spragens Director | Oct 1, 2021 | Buy | +13,000 | $10.07 | $130.91K | 13,000 |
| Russell P. Beyer Chief Financial Officer | Sep 29, 2021 | Award | +10 | $10.08 | $101 | 15 |
| Russell P. Beyer Chief Financial Officer | Sep 28, 2021 | Award | +149 | $10.08 | $1.50K | 149 |
| Russell P. Beyer Chief Financial Officer | Sep 28, 2021 | Award | +5 | $10.07 | $50 | 5 |
| Cypress Holdings LLC Big CEO and CFO, Director, 10% owner | Jan 14, 2021 | Buy | +417,200 | $10.00 | $4.17M | 3,047,825 |
| Samuel J. Reich CEO and CFO, Director, 10% owner | Jan 14, 2021 | Buy | +417,200 | $10.00 | $4.17M | 3,047,825 |
| Ilan Katz Director, 10% owner | Jan 14, 2021 | Buy | +417,200 | $10.00 | $4.17M | 3,047,825 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+78.0%
From 0M shares
Short volume, 20 days
23.4%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of SAB Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 477,370 shares on Aug 25, 2026 over the last 90 days.